





ACTIVE TARGETING SHIELDING LIPIDS

Partnered with





Tetradecylamine-PSar25-succ-CliCr®



Product No

CUR-L1529-25


MW (kDa) 2.0

PURITY >95%

CliCr®

50 mg 100 mg 1 g

N-ditetradecylamine-PSar50-succ-CliCr®



Product No

CUR-L1530-50


MW (kDa) 4.0

PURITY >95%

CliCr®

50 mg 100 mg 1 g

DMPE-PSar50-succ-CliCr®



Product No

CUR-L1531-50


MW (kDa) 4.2

PURITY >95%

CliCr®

50 mg 100 mg 1 g

DMG-PSar25-succ-CliCr®



Product No

CUR-L1532-25


MW (kDa) 2.3

PURITY >95%

CliCr®

50 mg 100 mg 1 g

DSG-PSar25-succ-CliCr®



Product No


CUR-L1533-25

MW (kDa) 2.4


PURITY >95%

CliCr®

50 mg 100 mg 1 g

**N,N-dihexadecylamine-PSar50-succ-Clickr®**

Product No

CUR-L1534-50

MW (kDa) 4.0

PURITY >95%

Clickr®


50 mg

100 mg

1 g

N-dioctadecylamine-PSar50-succ-Clickr®

Product No

CUR-L1524-50

MW (kDa) 4.1


PURITY >95%

Clickr®

50 mg

100 mg

1 g



All these products are modified using Clickr® conjugation technology and can be attached to the targeting ligand of your choice.


Curapath supports development from R&D to GMP-ready processes, enabling targeted LNP delivery (e.g. T cells, lung, brain) and extrahepatic biodistribution.

Advantages of combining Curapath's PEG alternatives with Clickr® technology on your LNP formulations

Better Safety profile (no PEG immunogenicity reactions)




Higher % LNP functionalization degree*




*vs. other conjugation technologies

Comparable profile (size, PDI, EE%) **to non-targeted LNPs**



Increased tissue selectivity






CURAPATH

ACTIVE TARGETING SHIELDING LIPIDS

Partnered with

Cristal
Therapeutics



www.curapath.com